Sanofi to test Parkinson's drug with Michael J. Fox Foundation

PARIS Thu Apr 19, 2012 11:27am IST

Related Topics

Stocks

   

PARIS (Reuters) - French drugmaker Sanofi said on Thursday it would collaborate with the Michael J. Fox Foundation to test an early- stage experimental treatment for Parkinson's disease.

Under the terms of the collaboration, MJFF will sponsor a phase I clinical trial to study the safety and tolerability of Sanofi's AVE8112, a drug that has shown promise in preclinical tests as a therapy for some of the psychiatric symptoms of the disease.

Parkinson's disease is a brain disorder that leads to shaking and difficulty with walking as well as mood changes and impaired memory.

All data and results generated by the clinical trial will be owned by MJFF and shared with Sanofi. Further development plans will be based on the results of the study, Sanofi said.

Patient enrollment in the study, which will be conducted in the U.S., is expected to begin later this year.

(Reporting by Elena Berton; Editing by Nina Sovich)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS EXCLUSIVE

HEALTH SHOWCASE

Marital Connection

Marital Connection

Spouse personality may affect career success  Full Article 

Influenza Vaccines

Influenza Vaccines

Plant-based vaccines challenge big pharma for $3 billion flu market  Full Article 

Ebola Outbreak

Ebola Outbreak

Traveler from Liberia is first Ebola patient diagnosed in U.S.  Full Article 

Birth Control

Birth Control

Long-acting reversible contraceptives best for teens: pediatricians.  Full Article 

Childhood Obesity

Childhood Obesity

Antibiotics in infancy may be linked to childhood obesity: study.  Full Article 

MERS Update

MERS Update

Austria reports first MERS case in Saudi national: media.  Full Article 

Sinusitis Drug

Sinusitis Drug

Sanofi-Regeneron drug has positive trial results in chronic sinusitis.  Full Article